Starpharma Holdings Limited’s (ASX: SPL) share price surged 3.387% to $1.282 after announcing that its proprietary DEP irinotecan development candidate showed complete tumour regression and 100% survival in a human pancreatic cancer model. This is compared with traditional irinotecan, Camptosar, alone and in combination with 5- fluorouracil.
In the study, human pancreatic tumour model did not respond to standard irinotecan regimen but Starpharma’s DEP irinotecan induced complete tumour regression and 100% survival.
The significant efficacy of DEP irinotecan defeats human pancreatic cancer which is a leading cause of death among oncologic diseases, with a one-year relative survival rate of 20%, and a five-year survival rate of only 7%. This result builds on efficacy data for DEP irinotecan in human colon cancer models, announced previously. [optin-monster-shortcode id=”wxhmli4jjedneglg1trq”]
As per the release, DEP irinotecan is now expected to enter the clinic in FY19 which will be the entry of Starpharma’s third internal DEP candidate to clinical development. Moreover, the company is currently engaged in completing final development and manufacturing of finished product and other trial preparations for DEP irinotecan phase 1 / 2 trial.
The Income available from dividends remains attractive for many investors.
We take a look at the best yields on the market and assess what they say about a company’s prospect.
One Thing is certain, though, Australia interest rates are still low, making income difficult to come by and keeping the focus for many investors on high yielding stocks. Kalkine’s team of analysts bought you handpicked report for “Top 25 Dividend Stocks For 2018.”
ASX-relevant Special Reports are published year-round to provide a detailed analysis into an investing opportunity or a potential risk to your portfolio.
Click here to get your free report.
The advice given by Kalkine Pty Ltd and provided on this website is general information only and it does not take into account your investment objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your investment objectives, financial situation and needs before acting upon it. You should seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice. Not all investments are appropriate for all people. Kalkinemedia.com and associated websites are published by Kalkine Pty Ltd ABN 34 154 808 312 (Australian Financial Services License Number 425376). website), employees and/or associates of Kalkine Pty Ltd do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations.